Skip to main content

Instil Bio, Inc.

corporate_fare Company Profile

Instil Bio, Inc.

TIL·NASDAQ·Life Sciences·CIK 0001789769

We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. Our wholly owned subsidiary, Axion Bio, Inc., discontinued development of AXN-2510 in January 2026. AXN-2510 was a bispecific antibody targeting programmed death-ligand 1 and vascular endothelial growth factors in solid tumor cancers, in-licensed from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in August 2024. The license and collaboration agreement with ImmuneOnco was terminated in January 2026. Previously, our development efforts focused on cell therapies, including our proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for cancer treatment. Our current strategy is to pursue potential acquisitions or in-licensing of therapeutic candidates. We are actively seeking to in-license or acquire and develop additional novel therapeutic candidates for diseases with significant unmet medical need.

Instil Bio, Inc. (NASDAQ:TIL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for TIL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for TIL spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Instil Bio 10-Q Discloses Material Weakness and Going-Concern Doubt on $85.6M Loan
  • Instil Bio Reports Sharply Reduced Q1 Loss, Extends Cash Runway Beyond 2027, Reverses Tarzana Facility Sale
  • Instil Bio Extends Cash Runway Beyond 2027, Mitigating Going Concern Risk
  • Instil Bio Posts Q1 Net Loss of $4.2M, EPS -$0.62, Reinforcing Going Concern Doubts
  • Instil Bio Discloses Going Concern Doubt, Discontinues Lead Product, and Reports Significant Asset Impairment in Annual Filing

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$71.37M
Diluted EPS
-$10.70
Op. Cash Flow
-$36.62M
Operating Income
-$78.58M
Cash & Equivalents
$6.64M
Debt / Equity
0.00×
Shares Outstanding
6.78M sh
Source: 10-K · filed 2026-03-27 · accession 0001789769-26-000019

Short Interest & Short Volume

2.28 days to cover

FINRA reported short interest of 181,228 shares in TIL as of the October 30, 2026 settlement, a 6.3% increase from the prior period — about 2.3 days to cover at its recent average daily volume. On November 20, 2026, 39.4% of TIL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)181,228 shares as of October 30, 2026
Change vs prior period▲ 6.3%
Days to cover2.28 at avg daily volume of 79,363
Daily short volume (FINRA facilities)39.4% of 24,908 shares on November 20, 2026
5-day average short volume52.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with T →
$5.45 -1.80% today
52-week range · as of 2026-11-16 $5.45 – $15.23
Market cap
$35.47M
Volume
64.3K (0.9× avg)
3-mo avg 71.7K
Live data · 2026-11-21 19:39 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TIL - Latest Insights

TIL
Nov 16, 2026, 7:17 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.08
Real-time Price: $5.45 info
Change: -$0.630 (-10%) info
Market Cap: $35.47M info
TIL
May 15, 2026, 8:31 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.34
Real-time Price: $5.45 info
Change: -$2.89 (-35%) info
Market Cap: $35.47M info
TIL
May 15, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.34
Real-time Price: $5.45 info
Change: -$2.89 (-35%) info
Market Cap: $35.47M info
TIL
May 15, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $8.00
Real-time Price: $5.45 info
Change: -$2.55 (-32%) info
Market Cap: $35.47M info
TIL
Mar 27, 2026, 7:05 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $8.36
Real-time Price: $5.45 info
Change: -$2.91 (-35%) info
Market Cap: $35.47M info
TIL
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.36
Real-time Price: $5.45 info
Change: -$2.91 (-35%) info
Market Cap: $35.47M info
TIL
Jan 06, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.75
Real-time Price: $5.45 info
Change: -$1.30 (-19%) info
Market Cap: $35.47M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets